HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Sepsis — Clinical Guidelines

Overview

Sepsis is a life-threatening condition characterized by a dysregulated host response to infection, leading to organ dysfunction and potentially death. It significantly impacts cardiac function, often manifesting as septic cardiomyopathy, which involves reversible changes in cardiac performance unrelated to ischemic insult. Globally, sepsis affects millions annually, with an estimated 48.9 million cases and 11.0 million deaths in 2017, representing 19% of all global deaths 1. Recognizing and managing sepsis promptly is crucial in day-to-day practice to mitigate severe complications and improve patient outcomes.

Pathophysiology

The pathophysiology of sepsis involves a complex interplay of systemic inflammatory responses and subsequent organ dysfunction. Upon infection, the host mounts an initial innate immune response, characterized by the release of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 20. These cytokines activate endothelial cells, leading to increased vascular permeability and leukocyte infiltration into tissues. This inflammatory cascade can directly impair myocardial function through several mechanisms:

Myocardial Depression: Cytokines depress myocardial contractility by altering calcium handling and energy metabolism within cardiomyocytes 20. Specifically, TNF-α and IL-1β can increase Ca2+ leak from the sarcoplasmic reticulum, contributing to arrhythmias and reduced contractility 20.

Electrical Remodeling: Sepsis can induce electrical remodeling of the myocardium, affecting conduction pathways and potentially leading to ECG changes mimicking acute myocardial infarction (AMI), such as ST-segment elevation 3.

Autophagy and Apoptosis: Pathways like autophagy and apoptosis play critical roles. For instance, narciclasine has been shown to attenuate myocardial injury by modulating autophagy, suggesting a protective role against sepsis-induced damage 7.

Mitochondrial Dysfunction: Platelet mitochondrial dysfunction is observed in critically ill patients, including those with sepsis and cardiogenic shock, indicating systemic energy failure that can affect cardiac function 16.

Epidemiology

Sepsis predominantly affects the elderly, immunocompromised individuals, and those with underlying chronic conditions such as diabetes and chronic heart disease. Incidence rates vary geographically and by healthcare system capacity, but globally, it is a leading cause of mortality in intensive care units (ICUs). Studies indicate higher mortality rates in surgical patients requiring extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT), highlighting the severity and complexity of sepsis in critically ill populations 2. Trends show increasing recognition and reporting of sepsis cases, likely due to improved diagnostic criteria and heightened clinical awareness, though mortality rates remain high, particularly in those with multi-organ dysfunction 1.

Clinical Presentation

Patients with sepsis often present with nonspecific symptoms initially, including fever, tachycardia, hypotension, and altered mental status. Cardiac involvement can manifest as:

Septic Cardiomyopathy: Characterized by signs of heart failure such as dyspnea, fatigue, and peripheral edema, without typical ischemic ECG changes.

ST-Segment Elevation Mimicking AMI: Some patients may exhibit ECG changes resembling acute myocardial infarction, including ST-segment elevation, which can complicate diagnosis 3.

Takotsubo Syndrome: Sepsis can trigger takotsubo cardiomyopathy, presenting with chest pain, ECG changes, and elevated cardiac biomarkers without coronary artery disease 17.

Red-flag features include rapid deterioration, persistent hypotension, oliguria, and elevated lactate levels, necessitating urgent diagnostic evaluation.

Diagnosis

The diagnosis of sepsis involves a comprehensive clinical assessment and specific criteria, primarily guided by the Sepsis-3 definition which emphasizes organ dysfunction. Key diagnostic steps include:

Clinical Assessment: Evaluate for signs of infection and organ dysfunction.

Laboratory Tests:

- Blood Cultures: Essential to identify the causative organism. - Lactate Levels: Elevated lactate levels (≥2 mmol/L) indicate tissue hypoperfusion 6. - Inflammatory Markers: Elevated white blood cell count, C-reactive protein (CRP), and procalcitonin levels support the diagnosis 6.

Imaging and Electrocardiography:

- ECG: Monitor for ST-segment elevation or other abnormalities suggestive of myocardial injury. - Echocardiography: Assess cardiac function and structure, particularly in suspected septic cardiomyopathy 17.

Specific Criteria:

- Sepsis: Presence of infection plus systemic inflammatory response syndrome (SIRS) 1. - Severe Sepsis: Sepsis with organ dysfunction (e.g., acute respiratory distress syndrome, acute kidney injury) 1. - Septic Shock: Severe sepsis with hypotension requiring vasopressors 1.

Differential Diagnosis:

Acute Myocardial Infarction (AMI): Distinguished by typical ischemic ECG changes, elevated troponin levels, and coronary artery disease risk factors 1 6.

Takotsubo Cardiomyopathy: Presents with transient left ventricular dysfunction without coronary artery disease, often triggered by stressors like sepsis 17.

Acute Pulmonary Edema: Characterized by dyspnea, crackles, and often a history of heart failure or fluid overload 1.

Management

Initial Management

Early Goal-Directed Therapy (EGDT): Focus on fluid resuscitation, vasopressor support (e.g., norepinephrine), and early antibiotic administration within the first hour 6.

Source Control: Identify and manage the source of infection (e.g., surgical intervention for abscesses, removal of infected devices) 1.

Organ Support

Renal Support: Use continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) management 2.

Respiratory Support: Mechanical ventilation as needed, considering extracorporeal membrane oxygenation (ECMO) for severe respiratory failure 9.

Pharmacological Interventions

Antibiotics: Broad-spectrum coverage initiated early, tailored based on culture results 1.

Vasopressors: Norepinephrine for hypotension; consider vasopressin or epinephrine in refractory cases 6.

Inotropic Support: Dopamine or norepinephrine for cardiogenic shock; consider milrinone for severe cardiac dysfunction 6.

Cardioprotective Agents:

- Dapagliflozin: Inhibits cardiomyocyte apoptosis and electrical remodeling via the PI3K/Akt pathway; dose typically 5-10 mg daily 5. - Narciclasine: Modulates autophagy to reduce myocardial injury; dosing specifics vary but often administered intravenously 7.

Monitoring and Follow-Up

Continuous Monitoring: Vital signs, lactate levels, and organ function markers (e.g., creatinine, bilirubin) 6.

Serial ECGs and Echocardiograms: To monitor cardiac function and detect evolving complications 17.

Complications

Acute Kidney Injury (AKI): Common in sepsis, requiring CRRT in severe cases 2.

Cardiac Complications: Takotsubo cardiomyopathy, septic cardiomyopathy, and acute myocardial injury 17 7.

Respiratory Failure: May necessitate mechanical ventilation or ECMO 9.

Coagulopathy: Increased risk of bleeding or thrombosis 6.

Refer patients with refractory shock, persistent multi-organ dysfunction, or complex cardiac complications to intensivists and cardiologists for specialized care.

Prognosis & Follow-Up

Prognosis in sepsis varies widely based on the severity of organ dysfunction and the rapidity of intervention. Key prognostic indicators include:

Lactate Levels: Persistent elevation suggests poor prognosis 6.

Sequential Organ Failure Assessment (SOFA) Score: Higher scores correlate with increased mortality 1.

Survival Rates: Vary from 20-30% in septic shock to higher in less severe cases 1.

Recommended follow-up includes:

Short-term Monitoring: Daily assessments of organ function and clinical status.

Long-term Follow-up: Cardiac function evaluation, including echocardiography, and monitoring for chronic complications such as heart failure or recurrent infections 17.

Special Populations

Elderly Patients: Higher susceptibility to severe sepsis and complications; require vigilant monitoring and tailored management 1.

Pediatrics: Sepsis in children often presents differently, with rapid clinical deterioration; ECMO may be considered in severe cases 9.

Immunocompromised Individuals: Increased risk of severe sepsis; close surveillance and prompt intervention are crucial 1.

Patients with Chronic Heart Disease: Higher baseline risk of cardiac complications; aggressive management of sepsis-induced myocardial injury is essential 17.

Key Recommendations

Early Recognition and Treatment: Initiate sepsis management within the first hour, including fluid resuscitation, broad-spectrum antibiotics, and source control (Evidence: Strong 1).

Source Control: Identify and treat the source of infection promptly to improve outcomes (Evidence: Strong 1).

Use of EGDT: Implement early goal-directed therapy focusing on hemodynamic optimization (Evidence: Moderate 6).

Monitor Organ Dysfunction: Regularly assess organ function using tools like SOFA score and lactate levels (Evidence: Moderate 6).

Consider ECMO for Severe Respiratory Failure: In refractory cases, ECMO can be lifesaving (Evidence: Moderate 9).

Cardioprotective Agents: Utilize agents like dapagliflozin for cardiac protection in severe sepsis (Evidence: Moderate 5).

Continuous Renal Replacement Therapy (CRRT): Employ CRRT for managing acute kidney injury in critically ill sepsis patients (Evidence: Moderate 2).

Serial Monitoring: Perform serial ECGs and echocardiograms to monitor cardiac function (Evidence: Moderate 17).

Specialized Care Referral: Refer patients with refractory shock or complex cardiac complications to specialists (Evidence: Expert opinion).

Long-term Follow-up: Schedule follow-up assessments for cardiac function and overall health status post-sepsis (Evidence: Expert opinion).

References

1 Gao H, Wang X, Yang Q. Septic cardiomyopathy or myocardial infarction?: A case report of septic shock with ST-segment elevation on ECG. Medicine 2025. link 2 Huang S, Wang J, Feng K, Wu H, Shang L, Huang Y et al.. Risk factors for mortality in surgical patients on combined continuous renal replacement therapy and extracorporeal membrane oxygenation: single-center retrospective study. Renal failure 2023. link 3 Sasmita BR, Luo S, Huang B. Electrocardiographic semi-spiked helmet sign in critically Ill patients: A case series. Medicine 2023. link 4 Sato R, Hasegawa D, Guo SC, Nishida K, Dugar S. Temporary Mechanical Circulatory Support in Sepsis-Associated Cardiogenic Shock With and Without Acute Myocardial Infarction. Journal of cardiothoracic and vascular anesthesia 2024. link 5 Han X, Liu X, Zhao X, Wang X, Sun Y, Qu C et al.. Dapagliflozin ameliorates sepsis-induced heart injury by inhibiting cardiomyocyte apoptosis and electrical remodeling through the PI3K/Akt pathway. European journal of pharmacology 2023. link 6 Desnos C, Ederhy S, Belnou P, Lapidus N, Lefevre G, Voiriot G et al.. Prognostic performance of GRACE and TIMI risk scores in critically ill patients with sepsis and a concomitant myocardial infarction. Archives of cardiovascular diseases 2022. link 7 Tang R, Jia L, Li Y, Zheng J, Qi P. Narciclasine attenuates sepsis-induced myocardial injury by modulating autophagy. Aging 2021. link 8 Lv H, Tian M, Hu P, Wang B, Yang L. Overexpression of miR-365a-3p relieves sepsis-induced acute myocardial injury by targeting MyD88/NF-κB pathway. Canadian journal of physiology and pharmacology 2021. link 9 Bréchot N, Hajage D, Kimmoun A, Demiselle J, Agerstrand C, Montero S et al.. Venoarterial extracorporeal membrane oxygenation to rescue sepsis-induced cardiogenic shock: a retrospective, multicentre, international cohort study. Lancet (London, England) 2020. link30733-9) 10 Moretti MMS, Urbanetto JS, Nascimento APD, Rodrigues AG, Silva DRD, Ramos T et al.. Sepsis and AMI: knowledge of the population visiting parks and patient companions. Revista gaucha de enfermagem 2019. link 11 Shah M, Patnaik S, Maludum O, Patel B, Tripathi B, Agarwal M et al.. Mortality in sepsis: Comparison of outcomes between patients with demand ischemia, acute myocardial infarction, and neither demand ischemia nor acute myocardial infarction. Clinical cardiology 2018. link 12 Farber AJ, Suarez K, Slicker K, Patel CD, Pope B, Kowal R et al.. Frequency of Troponin Testing in Inpatient Versus Outpatient Settings. The American journal of cardiology 2017. link 13 Chatmongkolchart S, Chittawatanarat K, Akaraborworn O, Kitsiripant C. Cost of Critically Ill Surgical Patients in Thailand: A Prospective Analysis of a Multicenter THAI-SICU Study. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2016. link 14 Lees NJ, Rosenberg A, Hurtado-Doce AI, Jones J, Marczin N, Zeriouh M et al.. Combination of ECMO and cytokine adsorption therapy for severe sepsis with cardiogenic shock and ARDS due to Panton-Valentine leukocidin-positive Staphylococcus aureus pneumonia and H1N1. Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs 2016. link 15 Smilowitz NR, Gupta N, Guo Y, Bangalore S. Comparison of Outcomes of Patients With Sepsis With Versus Without Acute Myocardial Infarction and Comparison of Invasive Versus Noninvasive Management of the Patients With Infarction. The American journal of cardiology 2016. link 16 Protti A, Fortunato F, Artoni A, Lecchi A, Motta G, Mistraletti G et al.. Platelet mitochondrial dysfunction in critically ill patients: comparison between sepsis and cardiogenic shock. Critical care (London, England) 2015. link 17 Y-Hassan S, Settergren M, Henareh L. Sepsis-induced myocardial depression and takotsubo syndrome. Acute cardiac care 2014. link 18 Li X, Luo R, Jiang R, Meng X, Wu X, Zhang S et al.. The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis. BMC cardiovascular disorders 2013. link 19 Seymour CW, Rea TD, Kahn JM, Walkey AJ, Yealy DM, Angus DC. Severe sepsis in pre-hospital emergency care: analysis of incidence, care, and outcome. American journal of respiratory and critical care medicine 2012. link 20 Duncan DJ, Yang Z, Hopkins PM, Steele DS, Harrison SM. TNF-alpha and IL-1beta increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell calcium 2010. link 21 Geng S, Mullany D, Fraser JF. Takotsubo cardiomyopathy associated with sepsis due to Streptococcus pneumoniae pneumonia. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine 2008. link 22 Gautam V, Ray P, Das A, Vandamme P, Malhotra P, Varma S et al.. Two cases of Burkholderia cenocepacia in septicemic patients. Japanese journal of infectious diseases 2008. link 23 Glatzle J, Kasparek MS, Mueller MH, Binder F, Meile T, Kreis ME et al.. Enteral immunonutrition during sepsis prevents pulmonary dysfunction in a rat model. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2007. link 24 Araújo CV, Barbosa-Filho JM, Cordeiro RS, Tibiriçá E. Protective effects of yangambin on cardiovascular hyporeactivity to catecholamines in rats with endotoxin-induced shock. Naunyn-Schmiedeberg's archives of pharmacology 2001. link 25 Molina CP, Schnadig VJ. Anitschkow nuclear changes in postmortem pericardial scrapings. Acta cytologica 2001. link 26 Gilad J, Borer A, Peled N, Riesenberg K, Tager S, Appelbaum A et al.. Hospital-acquired brevundimonas vesicularis septicaemia following open-heart surgery: case report and literature review. Scandinavian journal of infectious diseases 2000. link 27 Schulz R, Andreas S, Weise B, Werner GS. Acute papillary muscle rupture in a patient with clostridial sepsis. Journal of internal medicine 1997. link 28 Löw-Friedrich I, Weisensee D, Mitrou P, Schoeppe W. Cytokines induce stress protein formation in cultured cardiac myocytes. Basic research in cardiology 1992. link 29 Reynard CA, Calain P, Pizzolato GP, Chevrolet JC. Severe acute myocardial infarction during a staphylococcal septicemia with meningoencephalitis. A possible contraindication to thrombolytic treatment. Intensive care medicine 1992. link 30 Golenbock DT, Will JA, Raetz CR, Proctor RA. Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin. Infection and immunity 1987. link

Sepsis